Diyabet Komplikasyonları ile PON-1 Aktivitesinin Brakiyal Arter İntima- Media Kalınlığı (IMK) İlişkisi
Giriş: Diabetes mellitus, kardiyovasküler belirtilerin yanısıra kendi başlarına önemlibirer morbidite ve mortalite nedeni olan mikro ve makrovasküler komplikasyonlar içinde risk artışı ile ilişkili olup, oksidatif stresin ise diabetes mellitus ve ilgili komplikasyonlarıarasında köprü vazifesi gördüğü kabul edilmektedir.
___
- 1. Bo S, Ciccone G, Gancia R, Rosato R, Grassi G, Merletti F,
et al. Mortality within the first 10 years of the disease in type
2 diabetic patients. Nutr Metab Cardiovasc Dis 2006;16:8–12.
2. Beisswenger, P. J., Drummond, K. S., Nelson, R. G., Howell,
S. K., Szwergold, B. S., & Mauer, M. (2005). Susceptibility to
diabetic nephropathy is related to dicarbonyl and oxidative
stress. Diabetes, 54 (11), 3274 3281.
3. Bhatia, S., Shukla, R., Venkata Madhu, S., Kaur Gambhir, J.,
& Madhava Prabhu, K. (2003). Antioxidant status, lipid peroxidation
and nitric oxide end products in patients of type 2
diabetes mellitus with nephropathy. Clinical Biochemistry,
36(7), 557 562
4. Mastorikou, M, Mackness, M, Mackness, B. Defective metabolism
of oxidised-phospholipid by high-density lipoprotein from
people with type 2 diabetes. Diabetes 55 (2006). 3099-3103.
5. Haffner, S.M., Lehto, S., Ronnemaa, T., Pyorala, K., Laakso,
M., 1998. Mortality from coronary heart disease in subjects with
type 2 diabetes and in nondiabetic subjects with and without prior
myocardial infarction. N. Engl. J. Med. 339, 229-234.
6. Nathan, D.M., Meigs, J., Singer, D.E., 1997. The epidemiology
of cardiovascular disease in type 2 diabetes mellitus: how
sweet it is … or is it? Lancet 350 (Suppl. 1), SI4-SI9
7. Goswami B1, Tayal D, Gupta N, Mallika V. Paraoxonase: a
multifaceted biomolecule Clin Chim Acta. 2009 Dec;410(1-
2):1-12. Review.
8. Iwamoto Y, Maruhashi T, Fujii Y, et al. Intima-media thickness
of brachial artery, vascular function, and cardiovascular risk
factors. Arterioscler Thromb Vasc Biol 2012;32:2295-2303.
9. Picard S, Talussot C, Serusclat A, Ambrosio N, Berthezene F.
Minimally oxidised LDL as estimated by a new method increase
in plasma of type 2 diabetic patients with atherosclerosis
or nephropathy. Diabetes Metab Paris 1996;22:25-30.
10. ARIC study Investigators, Iribarren C, Folsom AR, Jacobs DR,
Gross MD Jr., Belcher JD, Eckfeldt JH. Association of serum
vitamin levels, LDL susceptibility to oxidation, and autoantibodies
against MDA-LDL with carotid atherosclerosis. Arterioscler
Thromb Vasc Biol 1997;17:1171-7.
11. Mackness B, Hunt R, Durrington PN, Mackness MI. increased
immunolocalization of parraoxonase, clusterin, and apolipoprotein
A-I in the human artery with the progression of
atherosclerosis. 1997;17:1233-38.
12. Mackness, B, Mackness, MI, Arrol, S, Turkie, W, Julier, K, Abuashia,
B, Miller, JE, Boulton, AJM, Durrington, PN. Serum
paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase
activity and concentration in non-insulin dependent diabetes
mellitus. Atherosclerosis 139 (1998), 341-349.
13. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents
accumulation of lipoperoxides in low-density lipoprotein. FEBS
Lett 1991;286:152-4.
14. Rozenberg O, Shiner M, Aviram M, Hayek T. Paraoxonase 1
(PON1) attenuates diabetes development in mice through its
antioxidative properties. Free Radic Biol Med. 2008 Jun
1;44(11):1951-9.
15. Goswami B1, Tayal D, Gupta N, Mallika V (2009) Paraoxonase:
a multifaceted biomolecule Clin Chim Acta 410:1-12. Review
16. Kosaka T, Yamaguchi M, Motomura T, Mizuno K (2005) Investigation
of the relationship between atherosclerosis and paraoxonase
or homocysteine thiolactonase activity in patients
with type 2 diabetes mellitus using a commercially available
assay. Clin Chim Acta 359:156-162.
17. Bansal S, Chawla D, Siddarth M, Banerjee BD, Madhu SV,
Tripathi AK (2013) A study on serum advanced glycation end
products and its association with oxidative stress and paraoxonase
activity in type 2 diabetic patients with vascular complications.
Clin Biochem 46:109-114.
18. Fleka M, krha J, Zídková K, Lacinová Z, Hilgertová J (2008)
Paraoxonase 1 gene polymorphisms and enzyme activities in
diabetes mellitus. Physiol Res 57:717-726.
19. Mastorikou M, Mackness B, Liu Y, Mackness M (2008) Glycation
of paraoxonase-1 inhibits its activity and impairs the ability
of high-density lipoprotein to metabolize membrane lipid
hydroperoxides. Diabet Med 25:1049-1055.
20. Mackness B, Mackness MI, Arrol S, et al(1998) Serum paraoxonase
(PON1) 55 and 192 polymorphism and paraoxonase
activity and concentration in non-insulin dependent diabetes
mellitus. Atherosclerosis 139:341-349.
21. Ikeda Y, Suehiro T, Inoue M, et al (1998) Serum paraoxonase
activity and its relationship to diabetic complications in patients
with non-insulindependent diabetes mellitus. Metabolism
47:598-602.
22. Sozmen EY, Sozmen B, Delen Y, Onat T (2001). Catalase/superoxide
dismutase (SOD) and catalase/paraoxonase (PON)
ratios may implicate poor glycemic control. Arch Med Res
32:283-287.
6 www.kliniktipdergisi.com
23. Abdin AA, Hassanien MA, Ibrahim EA, El-Noeman Sel-D
(2010) Modulating effect of atorvastatin on paraoxonase 1 activity
in type 2 diabetic Egyptian patients with or without nephropathy.
J Diabetes Complications 24:325-333.
24. Abbott CA, Mackness MI, Kumar S, Boulton AJ, Durrington
PN. (1995) Serum paraoxonase activity, concentration, and
phenotype distribution in diabetes mellitus and its relationship
to serum lipids and lipoproteins. Arterioscler Thromb Vasc
Biol 15:1812-1818.
25. Mackness B, Durrington PN, Abuashia B, Boulton AJ, Mackness
MI (2000) Low paraoxonase activity in type II diabetes mellitus
complicated by retinopathy. Clin Sci (Lond) 98:355-363.
26. Kota SK, Meher LK, Kota SK, Jammula S, Krishna SV, Modi
KD (2013) Implications of serum paraoxonase activity in obesity,
diabetes mellitus, and dyslipidemia. Indian J Endocrinol
Metab 17:402-412.
27. Gur M, Yildiz A, Demirbag R, et al (2007) Paraoxonase and
arylesterase activities in patients with cardiac syndrome X,
and their relationship with oxidative stress markers. Coron
Artery Dis 18:89-95.
28. Kasprzak M, Iskra M, Majewski W, Wielkoszy ski T (2009) Arylesterase
and paraoxonase activity of paraoxonase (PON1)
affected by ischemia in the plasma of patients with arterial occlusion
of the lower limbs. Clin Biochem 42:50-56.
29. Sumegova K, Blazicek P, Waczulikowa I, Zitnanova I, Durackova
Z (2006) Activity of paraoxonase 1 (PON1) and its relationship
to markers of lipoprotein oxidation in healthy Slovaks.
Acta Biochim Pol 53:783-787.
30. Ayub A, Mackness M, Arrol S, Mackness B, Patel J, Durrington
P (1999) Serum paraoxonase after myocardial infarction.
Arterioscler Thromb Vasc Biol 19:330-335.
31. Mackness MI, Arrol S, Durrington PN (1991) Paraoxonase
prevents accumulation of lipoperoxides in low-density lipoprotein.
FEBS Lett 286:152-154.
32. Dullaart RP, Otvos JD, James RW (2014) Serum paraoxonase-
1 activity is more closely related to HDL particle concentration
and large HDL particles than to HDL cholesterol in
Type 2 diabetic and non-diabetic subjects. Clin Biochem
47:1022-1027.
33. Watson AD, Berliner JA, Hama SY, et al (1995) Protective effect
of high-density lipoprotein associated paraoxonase—inhibition
of the biological activity of minimally oxidised lowdensity
lipoprotein. J Clin Invest 96:2882-2891.
34. Pasqualini L, Cortese C, Marchesi S, et al (2005) Paraoxonase-
1 activity modulates endothelial function in patients with
peripheral arterial disease. Atherosclerosis 183:349-354.
35. Cao H, Girard-Globa A, Serusclat A, et al (1998) Lack of association
between carotid intima-media thickness and paraoxonase
gene polymorphism in non-insulin dependent diabetes
mellitus. Atherosclerosis 138:361-366.
36. La Du BN, Piko JI, Eckerson HW, Vincent-Viry M, Siest G
(1986) An improved method for phenotyping individuals for
the human serum paraoxonase arylesterase polymorphism. Ann
Biol Clin 44:369-372.
37. Campo S, Sardo MA, Trimarchi G, et al (2004) The paraoxonase
promoter polymorphism (-107)T>C is not associated
with carotid intima-media thickness in Sicilian hypercholesterolemic
patients. Clin Biochem 37:388-394.
38. Mackness B, Marsillach J, Elkeles RS, et al (2012) Paraoxonase-
1 is not associated with coronary artery calcification in
type 2 diabetes: results from the PREDICT study. Dis Markers
33:101-112
39. Koren-Gluzer M, Aviram M, Meilin E, Hayek T (2011) The
antioxidant HDL-associated paraoxonase-1 (PON1) attenuates
diabetes development and stimulates -cell insulin release.
Atherosclerosis 219:510-518.
40. Kikkawa R, Koya D, Haneda M (2003) Progression of diabetic
nephropathy. Am Jof Kidney Dis 41(3 Suppl 1):S19-S21.